Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Obesity (Silver Spring). 2016 Nov 3;24(12):2553–2561. doi: 10.1002/oby.21633

Table 4.

Change in safety variables from randomization using completers only.

Outcome N Placebo Δ [mean (SD)] Topiramate Δ [mean (SD)] Mean Difference [Topiramate-Placebo] (95% CI) P-value
CANTAB
Standard PAL 21 −0.24 (0.23) 0.04 (0.60) 0.26 (−0.16, 0.69) 0.238
Standard PAL Shapes 21 −0.24 (0.53) 0.11 (1.62) 0.07 (−0.74, 0.88) 0.863
Standard PRM 21 0.24 (0.80) −0.64 (2.00) −0.70 (−2.13, 0.73) 0.348
Standard SSP 19 0.11 (0.79) 0.36 (1.21) 0.16 (−0.80, 1.11) 0.750

CPT-II
Omissions % 20 −0.09 (18.09) 0.34 (4.62) −3.81 (−13.72, 6.09) 0.461
Commissions % 20 2.20 (7.29) 1.55 (11.04) −0.30 (−8.01, 7.42) 0.941
Hit Reaction Time 20 6.37 (10.38) −2.67 (7.44) −11.13 (−18.32, −3.93) 0.008

BRIEF-SR
BRI T-score 15 1.17 (10.96) −1.00 (8.80) −1.97 (−10.57, 6.62) 0.661
MI T-score 14 0.33 (13.38) 0.00 (5.32) −0.64 (−10.50, 9.21) 0.900
GEC T-score 14 1.00 (12.81) −1.00 (7.52) −2.02 (−11.74, 7.71) 0.692

PAL, Paired Associates Learning; PRM, Pattern Recognition Memory; SSP, Spatial Span; BRI, Behavior Regulation Index; MI, Metacognition Index; GEC, Global Executive Composite